Research programme: antiviral antibodies - OPKO Health
Latest Information Update: 03 Oct 2023
At a glance
- Originator ModeX Therapeutics Inc
- Developer OPKO Health
- Class Antiretrovirals; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections; HIV infections
Most Recent Events
- 28 Sep 2023 ModeX Therapeutics Inc collaborates with the Biomedical Advanced Research and Development Authority (BARDA) for the development of antiviral antibodies
- 09 May 2022 ModeX Therapeutics Inc has been acquired by OPKO Health
- 09 May 2022 Preclinical trials in COVID-2019 infections in USA (Parenteral)